U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C50H73N15O11.3C2H4O2
Molecular Weight 1240.3644
Optical Activity UNSPECIFIED
Defined Stereocenters 8 / 8
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BRADYKININ TRIACETATE

SMILES

CC(O)=O.CC(O)=O.CC(O)=O.N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)NCC(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CO)C(=O)N4CCC[C@H]4C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O

InChI

InChIKey=GGIQAOBCVDFMSP-XFUQBTSGSA-N
InChI=1S/C50H73N15O11.3C2H4O2/c51-32(16-7-21-56-49(52)53)45(72)65-25-11-20-39(65)47(74)64-24-9-18-37(64)43(70)58-28-40(67)59-34(26-30-12-3-1-4-13-30)41(68)62-36(29-66)46(73)63-23-10-19-38(63)44(71)61-35(27-31-14-5-2-6-15-31)42(69)60-33(48(75)76)17-8-22-57-50(54)55;3*1-2(3)4/h1-6,12-15,32-39,66H,7-11,16-29,51H2,(H,58,70)(H,59,67)(H,60,69)(H,61,71)(H,62,68)(H,75,76)(H4,52,53,56)(H4,54,55,57);3*1H3,(H,3,4)/t32-,33-,34-,35-,36-,37-,38-,39-;;;/m0.../s1

HIDE SMILES / InChI

Molecular Formula C50H73N15O11
Molecular Weight 1060.2085
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 8 / 8
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula C2H4O2
Molecular Weight 60.052
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Bradykinin, a pro-inflammatory mediator is also a neuromediator and regulator of several vascular and renal functions. Bradykinin can act as a vasoactive substance along with histamine in inflammation and swelling as it is a potent vasodilator. In addition, it triggers the release of other mediators such as nitric oxide in inflammatory and cancer tissues. Bradykinin acts via specific cell surface receptors: bradykinin receptor, B1 and B2 that are G-protein coupled receptors of the seven-transmembrane domain family. It was shown that increased plasma levels of bradykinin lead to the angioedema as the common major clinical manifestation. Bradykinin was also studied in heart transplant recipients and in obesity patients, but these studies were terminated or withdrawn for different reasons. Bradykinin is also an important growth factor for many cancers. Bradykinin antagonists showed higher potency than standard anti-cancer drugs, without evident toxicity to the hosts, that is why they have great promise for the development of new anti-cancer drugs.

Approval Year

PubMed

PubMed

TitleDatePubMed
MRP transporters as membrane machinery in the bradykinin-inducible export of ATP.
2010-04
Enhancement of arachidonic acid signaling pathway by nicotinic acid receptor HM74A.
2006-06-23
S-Glutathiolation by peroxynitrite activates SERCA during arterial relaxation by nitric oxide.
2004-11
Multiple antimicrobial peptides and peptides related to bradykinin and neuromedin N isolated from skin secretions of the pickerel frog, Rana palustris.
2000-11-30
The involvement of K+ channels and Gi/o protein in the antinociceptive action of the gallic acid ethyl ester.
1999-08-20
Effects of mexiletine on algogenic mediator-induced nociceptive responses in mice.
1999-08-13
Molecular characterisation of cloned bradykinin B1 receptors from rat and human.
1999-06-25
Pharmacological modulation of secondary mediator systems--cyclic AMP and cyclic GMP--on inflammatory hyperalgesia.
1999-06
The nonpeptide B2 receptor antagonist FR173657: inhibition of effects of bradykinin related to its role in nociception.
1998-07
Stable expression of the human kinin B1 receptor in Chinese hamster ovary cells. Characterization of ligand binding and effector pathways.
1997-04-25
Novel subtype-selective nonpeptide bradykinin receptor antagonists FR167344 and FR173657.
1997-02
The agonist selectivity of a mouse B1 bradykinin receptor differs from human and rabbit B1 receptors.
1996-06
Cytokine-mediated inflammatory hyperalgesia limited by interleukin-10.
1995-06
BW373U86, a delta-opioid receptor agonist, reverses bradykinin-induced thermal allodynia in rhesus monkeys.
1995-04-24
S14080, a peripheral analgesic acting by release of an endogenous circulating opioid-like substance.
1995-01
Bradykinin-induced sensitization of afferent neurons in the rat paw.
1994-03
Mechanisms for protective effects of free radical scavengers on gentamicin-mediated nephropathy in rats.
1994-03
Differential pharmacology of cloned human and mouse B2 bradykinin receptors.
1994-01
Bradykinin-induced activation of nociceptors: receptor and mechanistic studies on the neonatal rat spinal cord-tail preparation in vitro.
1992-12
Kappa- and delta-opioids block sympathetically dependent hyperalgesia.
1991-04
Characterization of the arachidonic acid metabolites mediating bradykinin and noradrenaline hyperalgesia.
1988-08-23
Examinations on contribution of bradykinin in the action of dopamine in circulatory system of rats. I. Influence of bradykinin in the action of dopamine on arterial blood pressure of rats.
1983
Effects of prostacyclin on cardiovascular reflexes from the ventricular epicardium of the dog: comparison with the effects of prostaglandin E2.
1981-06
Patents
Substance Class Chemical
Created
by admin
on Mon Mar 31 22:58:39 GMT 2025
Edited
by admin
on Mon Mar 31 22:58:39 GMT 2025
Record UNII
6XS68K58Z5
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BRADYKININ ACETATE (1:3)
Preferred Name English
BRADYKININ TRIACETATE
Common Name English
BRADYKININ TRIACETATE SALT
Common Name English
ARGININE, N2-(N-(1-(N-(N-(N-(1-(1-L-ARGINYL-L-PROLYL)-L-PROLYL)GLYCYL)-3-PHENYL-L-ALANYL)-L-SERYL)-L-PROLYL)-3-PHENYL-L-ALANYL)-, TRIACETATE
Systematic Name English
Code System Code Type Description
FDA UNII
6XS68K58Z5
Created by admin on Mon Mar 31 22:58:39 GMT 2025 , Edited by admin on Mon Mar 31 22:58:39 GMT 2025
PRIMARY
CAS
5979-11-3
Created by admin on Mon Mar 31 22:58:39 GMT 2025 , Edited by admin on Mon Mar 31 22:58:39 GMT 2025
PRIMARY
PUBCHEM
12358884
Created by admin on Mon Mar 31 22:58:39 GMT 2025 , Edited by admin on Mon Mar 31 22:58:39 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY